Stay updated on Low Dose Sulindac & Eflornithine for FAP Clinical Trial

Sign up to get notified when there's something new on the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the number of polyps in patients with familial adenomatous polyposis (FAP) being studied in a phase III trial evaluating the combination of eflornithine and sulindac.
    Difference
    0.1%
    Check dated 2024-06-06T14:20:24.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for participants, including specific health conditions and prior treatments required for inclusion in the study. Previously, this section only indicated that no information was provided about collaborators.
    Difference
    39%
    Check dated 2024-05-22T21:04:13.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:19:14.000Z thumbnail image

Stay in the know with updates to Low Dose Sulindac & Eflornithine for FAP Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Low Dose Sulindac & Eflornithine for FAP Clinical Trial page.